

Cancer Genetic Markers of Susceptibility

Stephen J Chanock, M.D. November 29, 2006




http://cgems.cancer.gov

Mission of CGEMS




Conduct genome-wide SNP scans in Prostate cancer (1 in 8 men) Breast cancer (1 in 9 women) Analyze and publish findings **Rapid sequential replication studies Aggressive timeline** Initial scan in nested case-control studies from Prostate, Lung, Colon, Ovary (PLCO) Project **Nurses' Health Study**

Replication Strategy for Prostate Cancer



Power of the first two phases of CGEMS Point wise significance 10⁻⁷; "genome wide" significance 0.05



Continuous line : power for direct detection ($r^2 = 1$)
Dashed line : power for r ² = 0.8	

GRR

2.0

1.5

1.4

1.0

1.0

1.0

1.5

1.4

1.3

1.5

1.8

1.69

Recessive

Dominant

Additive

Multiplicative 1.3





Prostate Cancer


Breast Cancer

Two Scans
Illumina317k240k
(Feb 2007)

One Scan Illumina 550k (March 2007)

Incidence Density Sampling


Recruitment



Aggressive Prostate Cancer

- High priority to examine early vs aggressive
- Cohort based studies (screening)
 Bias towards early cases
- Enrich primary scan with >55% aggressive:45% early
 - Aggressive defined as:
 - Gleason >7 +/or Stage C/D
 - Follow-up studies in cohorts
 - Comparable distributions for early/advanced


Inclusion in CGEMS from PLCO of prostate cancer patients



Matching with controls was performed for 737 aggressive cases and 493 randomly selected non-aggressive cases.

> Non aggressive : stage <=2 (non invasive) and Gleason score <=6 Aggressive : stage >=3 (invasive) and Gleason score >=7

Distribution of genotyped individuals used for the search of association




Buccal Cell DNA and Infinium[™] II: ACS:CGEMS Pilot

23 matched blood and buccal Archived Buccal samples (2001/2002 in CPS-II) Swish with Scope[™] and store after centrifugation Extracted simultaneously with Autopure (Gentra) Target 50ng/uL by QDNA (picogreen) 4 outliers (0.5ng/uL- 35ng/uL) HumanHap300 Infinium[™] II protocol Completion 99.02% Concordance 99.96%


PLCO WGS QC


Removal of Inconsistent Genotypes Low Completion Rate (<95%) Duplicates: HapMap & PLCO qc samples Fitness for HW Proportion in controls Exclusion Cut-off: <0.001 **Re-Map SNP Positions** Examine adjacent bps of SNPs Heterogeneity in Cases/Controls Cryptic stratification STRUCTURE (Pritchard) Principal Component Analysis (Price Nat Gen 2006) Study Center (9 for PLCO)

Discordance rate




log-log quantile plot of p-value for Hardy-Weinberg proportion







Log-Log quantile plot for p-value for the 4 statistical tests used 307,256 SNPs




Log/log quantile plot of p value (observed)




PLCO Recruitment Sites Opportunity to look at geographic differences



Admixture coefficient in PLCO samples




Log-Log quantile plot for p-values of 101 SNPs that differentiate the populations of South and North of Europe




Seldin et al. PLOS Genetics 2:1339-1351 (2006)

Lactase region



Log₁₀Pvalue of the 4 d.f. χ 2 test plotted against the position of the 8q24 SNP (rs#1447295)* in build 35



Characteristics of the SNPs demonstrating the strongest signal of association in 8q24

positio			completic	•		
rsnumber (b	o.35)	CO	ntrols rat	е		
	MAF					
98. rs4242382	128586755	.14	.7604	1		
99. rs7017300	128594450	.18	.1629	1	i.	
00. rs7837688	128608542		.8663	.999	Ξ.	
800. rs7837688 801. rs1447295	128554220	.14	.6012		Τ.	+
	+					
			1			

Linkage disequilibrium (r²) with **rs1447295** of the SNPs demonstrating the strongest signal of association

				r2 with
Ι	rs# pos (b. :	ition rs14 35)	447295	passoc
I	rs4242382	128586755	.94	.00007
I	rs7017300	128594450	.71	.00009
I	rs7837688	128608542	.84	.00003
I	rs1447295	128554220	-	.0003

Prostate Scan 8q24 Region

			Genotype RR	for Indolent	Genotype RR for aggressive		
rs number	susceptibility	allele	Heterozyg.	Homozig.	Heterozyg.	Homozig.	
13 Humber	allele	frequency	neterozyg.	Homozig.	neterozyg.		
rs1447295	Α	0.1	1.08	1.45	1.24	1.46	
rs4242382	Α	0.1	1.13	1.39	1.27	1.39	
rs7017300	С	0.13	1.14	1.63	1.17	1.37	
rs7837688	Т	0.1	1.14	1.36	1.26	1.54	

Key Findings:

- 1. Comparable risk as original reports in Nat Genet and PNAS
- 2. Comparable risk for BPC3 (~6500 cases/controls)
- 3. Discovery of 1 and perhaps 2 additional loci

Value-Added Analysis CGEMS



Opportunity to investigate

- Gene:environment
 - Covariates: BMI, smoking, serum levels
- Multi-SNP Analysis
- Gene:gene interactions
 - Explore pathways
- Follow-up in cohort studies in CGEMS



Cancer Genetic Markers of Susceptibility Project

The Cancer Genetic Markers of Susceptibility (CGEMS) is a three-year, \$14 million initiative that will identify genetic alterations that make people susceptible to prostate and breast cancer. Scientists involved will use DNA available from five large studies of prostate cancer and five large studies of breast cancer to "scan" the genome for common genetic variations between patients who have these cancers and controls who do not have cancer.

Learn more >>

Spotlight

Cancer Genetic Markers of Susceptibility (CGEMS) February 13, 2006 NCI begins studies to identify genetic risk factors for prostate and breast cancer. <u>more</u>

DCEG and CGF Collaborate on CGEMS Initiative

Background

CGEMS: caBIG Posting Pre-Computed Analysis



This is the home page of the <u>Cancer Genetic Markers of Susceptibility</u> (CGEMS) data access. The following links provide information on the <u>project</u> and <u>background</u>. The CGEMS study design uses cases and controls drawn from well designed epidemiological studies of prostate and breast cancer. DNA from these subjects is being used to generate genotypes to perform a Genome-Wide Association Study (GWAS) on over 500,000 genetic variants to determine their role in cancer susceptibility.

CGEMS Prostate Scan Phase 1

A GWAS has been conducted in a large, national study in the U.S.A., the Prostate, Lung, Colorectal, and Ovary study (<u>PLCO</u>). The analysis includes 1,177 subjects who developed prostate cancer during the observational period and 1,105 individuals who did not develop prostate cancer during the same time period. The prostate scan is being conducted in two parts, Phase 1A and Phase 1B

The data generated from these scans can be accessed through this portal. The first posting includes data from Phase 1A of the prostate cancer scan and includes:

- Association test results for over 300,000 SNPs
- Frequency and descriptive statistics on these SNPs
- Individual phenotypic and genotypic data for the study participants and control samples. Note that these data can only be made available to eligible investigators after a registration process (link).

The results of Phase 1B will be available in February 2007.

Browse Data Bulk Data Download
For more information on:
About CGEMS Study How to use the CGEMS data portal Register to access raw data
Click the question mark icon for context sensitive help throughout the application.
CGEMS updates: • This release, Version 1.0, was deployed on Oct 10, 2006.
 The current dataset in use was deployed on Oct 10, 2006

Pre-computed Analysis No Restrictions

Raw Genotype Case/control Age (in 5 yrs) Family Hx (+/-) Registration

Association Finding

CGEMS Search Associations					Login		
 <u>About</u> <u>Browse Data</u> <u>Bulk Data Download</u> <u>Feedback</u> 	Study: CGEMS Prostate Scan 1 Search Association Findings by:						
	Analysis Name: Analysis Abstract:	contigency table tes Perform association an		uare 2			
	Genomic Location: (Based on Genome bui	ild 35)	Chromosome From To		bp 🗸		
	HUGO Gene Symbol Li (Fill in new line separa a list file with max. 10 via Browse button)	ated list or upload			bp 💌		
	dbSNP Identifier List (Fill in new line separa a list file with max. 10 Browse button)				Browse		
	Op-value OWhole Genome Ran		=		AND		
		Subn	nit Reset				

Association Finding Report



CGEMS SNP Association Finding Report

- About
- o Browse Data
- Bulk Data Download
- Feedback

Study: CGEMS Prostate Scan 1

SNP Association Finding Report - (38 findings)

Login

dbSNP ID	Chromosome	Physical Position (bp)	Associated Genes	Analysis Name	p-value	Whole Genome Rank
rs2803291	1	1924487	KIAA1751	score test	0.90626	273931
rs4648592	1	1833196	GNB1	score test	0.042421	12776
rs6603793	1	1590522	HSPC182	score test	0.475174	143777
rs6675798	1	1216520	B3GALT6 Cab45 LOC388581	score test	0.98977	298748
rs6681938	1	1813382	GNB1	score test	0.200469	60571
rs11721	1	1192554	B3GALT6 TNFRSF18 TNFRSF4 Cab45	score test	0.951451	287492

Population Frequency Report

Study: CGEMS Prostate Scan 1

EMS SNP Population Frequency Report

Login

About Browse Data 3ulk Data Download -eedback

dbSNP ID	Chromosome	Physical Position (bp)	Associated Genes	Population	Completion Rate (N/M)	Hardy Weinberg pValue	Allele	Allele Count (Frequency)	Genotype	Genotype Count (Frequency)
rs12726255	1	1089873		CONTROL	100 (1104/1104)	0.14233	A G	1890(0.856) 318(0.144)	AA AG GG	815(0.738) 260(0.236) 29(0.026)
rs6687776	1	1070488	FL)20584	CONTROL	100 (1104/1104)	0.595514	C T	1830(0.829) 378(0.171)	СС СТ П	761(0.689) 308(0.279) 35(0.032)
rs4970357	1	1116987	LOC254099	CONTROL	100 (1104/1104)	0.066365	A C	1985(0.899) 223(0.101)	AA AC CC	898(0.813) 189(0.171) 17(0.015)
rs2474460	1	1876208	CAGLP LOC339456 LOC339457	CONTROL	99.9094 (1103/1104)	0.809619	G A	1125(0.51) 1081(0.49)	GG GA AA	289(0.262) 547(0.496) 267(0.242)
rs4970420	1	1146396	FLJ36119	CONTROL	99.3659 (1097/1104)	0.771619	G A	1770(0.807) 424(0.193)	GG GA AA	712(0.649) 346(0.315) 39(0.036)
rs7531583	1	1738322	FL)13052	CONTROL	99.0036 (1093/1104)	0.618021	G A	1663(0.761) 523(0.239)	GG GA AA	629(0.575) 405(0.371) 59(0.054)
rs3820011	1	1920355	KIAA1751	CONTROL	99.8188 (1102/1104)	0.153441	G T	1592(0.722) 612(0.278)	GG GT TT	565(0.513) 462(0.419) 75(0.068)

SNP Frequency Report - (39 findings)

Acknowledgements

CGEMS Cancer Genetic Markers of Susceptibility

NCI

Gilles Thomas Robert Hoover Joseph Fraumeni Daniela Gerhard Kevin Jacobs Zhaoming Wang Meredith Yeager Robert Welch Richard Hayes Sholom Wacholder Nilanjan Chatterjee Kai Yu Margaret Tucker Marianne Rivera-Silva

HSPH

David Hunter Peter Kraft

ACS

Heather Feigelson Carmen Rodriguez Eugene Calle Michael Thun